The model excelled in de novo antibody design, significantly improving binding metrics, such as interaction energy for a hepatitis C peptide (-62.6 to -175.8 kcal/mol) and increasing polar contacts (8 to 31). It also generated novel CDRs for VEGF and fluorescein with binding performance comparable to experimentally optimized antibodies. Here, VEGFA is linked to hepatitis A virus infection.